The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | BTK inhibitors in CLL: sequencing, combinations, and advice for the community
In this discussion, Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, Jennifer Woyach, MD, The Ohio State University, Columbus, OH, and Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, speak on the role of BTK inhibitors (BTKi) in the management of chronic lymphocytic leukemia (CLL). The experts begin by discussing how molecular profiling influences BTKi selection and whether patients should be tested for BTK mutations or other resistance mutations before treatment and at relapse. They then share insights into key topics, including sequencing of BTKis with other therapeutic options, BTKi-containing combination approaches, and the treatment of patients with TP53 aberrations. Finally, they wrap up the discussion by focusing on the management of CLL in the community setting, providing valuable advice for community physicians and outlining how they approach decision-making in their clinical practice. This discussion took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
